A novel noncoding RNA and human lung cancers with inactivated LKB1 signaling
A novel noncoding RNA and human lung cancers with inactivated LKB1 signaling
批准号:
8881623
负责人:
Lizi Wu
金额:
$19.11万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-04-21 至 2017-03-31
关键词:
AddressBiological AssayBiological MarkersCREB1 geneCancer EtiologyCancer cell lineCell ProliferationCell SurvivalCessation of lifeClinicalCyclic AMPDNA Sequence AlterationDataDetectionDevelopmentDiagnosticEpigenetic ProcessEvaluationEventFreezingGene ExpressionGene TargetingGenesGenetic TranscriptionGrowthHumanIn VitroKRAS2 geneLinkLung AdenocarcinomaLung NeoplasmsMalignant NeoplasmsMalignant neoplasm of lungMediatingMetabolismMicroarray AnalysisModelingMolecularMusMutateMutationNeoplasm MetastasisNon-Small-Cell Lung CarcinomaNormal CellOncogenesPathway interactionsPatientsPilot ProjectsProtein-Serine-Threonine KinasesProteinsRegulationRegulator GenesResearchRoleSTK11 geneSignal TransductionStratificationStructureTechnologyTestingTranscriptional ActivationTumor Suppressor ProteinsUnited StatesUntranslated RNAUp-RegulationValidationVisionWomanaccurate diagnosisbasecancer cellcell behaviorchemotherapycohortdigitalfunctional lossgene functionin vivoinsightlung tumorigenesismenmouse modelnano-stringnoveloutcome forecastoverexpressionprognosticpublic health relevancerapid diagnosisresponsetherapeutic targettumortumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Lung cancer is the leading cause of cancer deaths in both men and women in the United States and worldwide. The tumor suppressor LKB1 gene - a gene encoding a serine/threonine kinase that is critical for cellular metabolism, polarity and growth control - is somatically inactivated in approximately 30% of non small cell lung cancer (NSCLC) cases, ranking it as the third most frequently mutated gene in NSCLC. The loss of LKB1 in the context of KRAS mutations promotes lung cancer metastasis in mouse models, and is associated with poor prognosis. The LKB1 status is linked with cancer responsiveness to several targeted agents and chemotherapy in mouse tumor models. LKB1 is thus implicated as diagnostic, prognostic and predictive biomarkers in human lung cancer. However, before clinical benefits that exploit LKB1 deficiency can be achieved, we need to have reliable assays to score tumors with LKB1 functional loss and to further understand the molecular basis for LKB1 tumor suppressor function and its clinical implications. Long noncoding RNAs (lncRNAs) have emerged as a novel class of gene regulators in recent years and are implicated in oncogenesis. We have observed a tight correlation between up-regulated expression of a lncRNA (LINC00473) and LKB1 inactivation in a panel of human NSCLC cell lines. Moreover, overexpression of LKB1 decreased LINC00473 expression, while LKB1 depletion enhanced it. Importantly, our pilot study revealed high LINC00473 expression in human primary lung tumors with downregulated LKB1 protein. Functionally, LINC00473 depletion reduced lung cancer cell proliferation and survival. Our overall preliminary data led us to hypothesize that LKB1 inactivation mediates LINC00473 transcriptional up-regulation and that the induced LINC00473 up-regulation contributes to lung tumorigenesis. This hypothesis will be addressed by two specific aims. Aim 1 will investigate molecular mechanisms underlying LKB1 regulation of LINC00473 expression and assess LINC00473 up-regulation as a biomarker for LKB1-inactivated lung cancers. Aim 2 will determine the role and mechanisms of LINC00473 in regulating lung cancer. The successful completion of these aims will provide significant insights into the roles and mechanisms of LINC00473 in lung tumorigenesis and has the potential to reveal novel biomarkers and potential therapeutic targets for lung cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanisms of Oncogenesis Research Program
-
批准号:10625757
-
项目类别:
-
资助金额:$7.78万
-
财政年份:2023
-
负责人:Lizi Wu
-
依托单位:
Aberrant CRTC activation as a unique vulnerability of lung cancer with LKB1 inactivation
-
批准号:10334407
-
项目类别:
-
资助金额:$33.57万
-
财政年份:2019
-
负责人:Lizi Wu
-
依托单位:
Aberrant CRTC activation as a unique vulnerability of lung cancer with LKB1 inactivation
-
批准号:10558734
-
项目类别:
-
资助金额:$33.54万
-
财政年份:2019
-
负责人:Lizi Wu
-
依托单位:
Signaling and targeting of CRTC1-MAML2 fusion oncoprotein in salivary gland tumor
-
批准号:8696318
-
项目类别:
-
资助金额:$37.75万
-
财政年份:2014
-
负责人:Lizi Wu
-
依托单位:
Signaling and Targeting of CRTC1-MAML2 Fusion Oncoprotein in Salivary Gland
-
批准号:10439473
-
项目类别:
-
资助金额:$35.15万
-
财政年份:2014
-
负责人:Lizi Wu
-
依托单位:
Signaling and targeting of CRTC1-MAML2 fusion oncoprotein in salivary gland tumor
-
批准号:8907995
-
项目类别:
-
资助金额:$37.65万
-
财政年份:2014
-
负责人:Lizi Wu
-
依托单位:
Signaling and Targeting of CRTC1-MAML2 Fusion Oncoprotein in Salivary Gland
-
批准号:10208855
-
项目类别:
-
资助金额:$35.57万
-
财政年份:2014
-
负责人:Lizi Wu
-
依托单位:
Signaling and Targeting of CRTC1-MAML2 Fusion Oncoprotein in Salivary Gland
-
批准号:10672248
-
项目类别:
-
资助金额:$35.43万
-
财政年份:2014
-
负责人:Lizi Wu
-
依托单位:
Transformation of Epithelial Cell by E6 Oncogene
-
批准号:7317800
-
项目类别:
-
资助金额:$16.02万
-
财政年份:2003
-
负责人:Lizi Wu
-
依托单位:
Transformation of Epithelial Cell by E6 Oncogene
-
批准号:6752507
-
项目类别:
-
资助金额:$28.26万
-
财政年份:2003
-
负责人:Lizi Wu
-
依托单位:
Transformation of Epithelial Cell by E6 Oncogene
-
批准号:6897945
-
项目类别:
-
资助金额:$28.26万
-
财政年份:2003
-
负责人:Lizi Wu
-
依托单位:
Transformation of Epithelial Cell by E6 Oncogene
-
批准号:7247186
-
项目类别:
-
资助金额:$20.52万
-
财政年份:2003
-
负责人:Lizi Wu
-
依托单位:
Transformation of Epithelial Cell by E6 Oncogene
-
批准号:6619209
-
项目类别:
-
资助金额:$28.26万
-
财政年份:2003
-
负责人:Lizi Wu
-
依托单位:
Transformation of Epithelial Cell by E6 Oncogene
-
批准号:7070053
-
项目类别:
-
资助金额:$11.58万
-
财政年份:2003
-
负责人:Lizi Wu
-
依托单位:
海外基金